Author: Thiru

Norway delivered the following statement on non-violation and situation complaints at the June 2015 meeting of the WTO TRIPS Council.

As delivered

TRIPS COUNCIL MEETING 9 AND 10 JUNE 2015

6. NON-VIOLATION AND SITUATION COMPLAINTS

Statement by Norway

***

• We would like to join the overwhelming majority of members that have intervened today.

Continue Reading →

On Wednesday, 10 June 2015, Norway – a high-income member of the WTO with a GDP per capita of 100,898 USD- (Source: World Bank, 2013) delivered this powerful intervention supporting the LDC Group request for an extension of the transition period for pharmaceutical products. On the LDC Group’s specific request on extension until graduation, Norway said,

Continue Reading →

On Tuesday, 9 June 2015, India delivered the following statement on Non-Violation and Situational Complaints (IP/C/W/385/Rev 1). Brazil introduced the paper along with 16 other WTO members including India. The 17 co-sponsors of this paper include Argentina, Plurinational State of Bolivia, Brazil, China, Colombia, Cuba, Ecuador, Egypt, India, Indonesia, Kenya, Malaysia, Pakistan, Peru, Russian Federation, Sri Lanka and Bolivarian Republic of Venezuela.

The joint submission proposes the following action item for the Nairobi Ministerial from 15 December 2015 to 18 December 2015:

Continue Reading →

The LDC Group delivered the following statement on Wednesday, 8 June 2015 during WTO TRIPS Council discussions on their request on the extension of the decision on pharmaceutical products.

PRESENTATION BY THE LDCS GROUP TO THE TRIPS COUNCIL ON THE EXTENSION OF THE DECISION ON PHARMACEUTICAL PRODUCTS, 09-10 JUNE 2015

Mr. Chairman,

I make this presentation on behalf of the LDCs group. We thank you for calling this meeting and for your report.

Continue Reading →

Today, on Wednesday, 10 June 2015, the World Trade Organization’s TRIPS Council discussed the LDC Group’s Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement (Source: IP/C/W/605). Continue Reading →

The following statement was delivered by the European Union at the February 2015 session in response to the proposal by the LDC Group Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement.

In particular, the European Union noted,

Continue Reading →